Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists
AbstractSince its discovery, the thrombopoietin (TPO) pathway has been an important pharmaceutical target for the treatment of thrombocytopenia. The first generation of TPO mimetics included peptide agents sharing homology with endogenous TPO, but these introduced a risk of antibody formation to endogenous TPO and were not successful. However, second-generation TPO mimetics or TPO receptor agonists (RAs) are currently being used to treat thrombocytopenia associated with a number of conditions, such as immune thrombocytopenia (ITP), severe aplastic anaemia (SAA), and hepatitis C virus-associated chronic liver disease. Accumulating efficacy and safety data suggest that the role of TPO-RAs in the treatment of thrombocytopenia may evolve in the near future with broader use of these agents in ITP and SAA, as well as approval in other indications, potentially including myelodysplastic syndromes, chemotherapy-associated thrombocytopenia, and post-transplant thrombocytopenia. This review provides an overview of clinical data on the efficacy and safety of TPO-RAs, emphasising recent findings that may expand their clinical utility.
TESTICULAR CANCER symptoms are treated very effectively with chemotherapy, and scientists have just discovered why.
Condition: Chemotherapy-induced Oral Mucositis Interventions: Drug: Gum Arabic; Drug: Chemotherapy; Behavioral: Lifestyle counseling Sponsor: University of Science and Technology, Yemen Completed
Conditions: Stomach Neoplasm; Peritoneal Carcinomatosis Interventions: Procedure: Cytoreductive surgery + Gastrecomy; Drug: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Sponsors: The Netherlands Cancer Institute; Erasmus Medical Center; St. Antonius Hospital; University Medical Center Groningen; Catharina Ziekenhuis Eindhoven Recruiting
Condition: Osteochondral; Defect Interventions: Procedure: autologous osteo-periosteal cylinder graft transplantation; Procedure: autologous osteochondral graft transplantation Sponsor: Peking University Third Hospital Not yet recruiting
Conditions: Pregnancy Complications; Anemia, Iron Deficiency; H Pylori Infection Interventions: Drug: triple attack therapy; Drug: Ferrous(II)-glycine-sulphate complex 567.7 mg capsules Sponsor: Kasr El Aini Hospital Not yet recruiting
Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer progressing on standard therapies. Here, we describe the clinical history of a 63-year-old male patient who was treated with regorafenib in the pivotal CORRECT trial. The patient was initially diagnosed in November 2008 with nonmetastaticKRAS-mutated (exon 2, codon 12) rectal cancer. He underwent successful surgery and was treated with 5 cycles of adjuvant chemotherapy. In 2010, lung metastases (KRAS-mutated) were detected and the patient received ...
In conclusion, the data presented in this paper should prompt other population studies focused on DRB3/4/5 genes and be used as a basis for future investigations of the clinical relevance of these genes in transplantation setting.
On 31 October 2017, at the American Society for Reproductive Medicine in San Antonio, Patel and colleagues presented the first study to correlate chemotherapy-treated women with reduced fertility of the offspring
Oncologists throughout France have joined the U.S.-based National Comprehensive Cancer Network (NCCN) in upgrading their recommended standard-of-care treatment regimen for unresectable pleural mesothelioma. Both groups have added bevacizumab (Avastin) to the traditional cisplatin and pemetrexed chemotherapy combination, expecting to see longer patient survival. “This is a major advancement for the care of mesothelioma patients,” Dr. Gerard Zalcman, head of thoracic oncology at Bichat-Claude Bernard Hospital, told Asbestos.com. “Clearly, this drug can change the natural history of this tumor.” Bevaci...